Can We Limit the Consequences of FDA's Aduhelm Approval?

Public and private payers may act as checks on the controversial decision

Related Keywords

Michael Gusmano ,Karenj Maschke ,National Coverage Determination ,Kaiser Family Foundation ,Medpage Today ,Medicare Administrative Contractors ,Medicare Part ,National Association ,Medicaid Directors ,Alzheimer 039s Disease ,Clinical Trial ,Clinical Trials ,